Refresh Virtual: Immuno-oncology - The Investor's Perspective

Immuno-oncology has created a lot of hype in biotech in recent years. Companies in the field are largely attracting the most attention, capital and licensing deals. But will the hype last? Karl Nägler, a veteran biotech venture capitalist and Managing Partner at Wellington Partners, gave us an investor's point of view about this topic.

---

Join our membership program "Labiotech Insider":
https://www.labiotech.eu/membership/

[What is Labiotech Insider?]
Labiotech Insider is our membership program that helps biopharma leaders stay ahead with access to exclusive stories, premium research, invites to Labiotech events and much more.

---

About Labiotech.eu:
Labiotech.eu is the leading digital media covering the European Biotech industry. Over 150,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Hope you'll enjoy reading our stories!

Facebook: https://www.facebook.com/Labiotech.eu
Twitter: https://twitter.com/Labiotech_eu
Linkedin: https://www.linkedin.com/company/labiotech-eu
Instagram: https://www.instagram.com/labiotech.eu
Meetup: https://www.meetup.com/Labiotech-Meetup/

Видео Refresh Virtual: Immuno-oncology - The Investor's Perspective канала Labiotech.eu